

Enfuvirtide TORO studies: 48 week results confirm 24 week findings

Katlama C¹, Arastéh K², Clotet B³, Cooper D⁴, Henry K⁵, Lalezari J⁶,
Lazzarin A⁷, Montaner J⁸, Nelson M⁹, O'Hearn M¹⁰, Piliero P¹¹, Reynes J¹²,
Trottier B¹³, Walmsley S¹⁴, DeMasi R¹⁵, Delehanty J¹⁵, Chung J¹⁶,
Salgo M¹⁶

¹Pitié-Salpêtrière Hosp., Paris, France; ²EPIMED, Berlin, Germany;

³Hosp. Germans Trias i Pujol, Barcelona, Spain; ⁴NCHECR, Sydney, Australia;

⁵HCMC, MN, US; ⁶Quest Clin. Res., CA, US; ⁷San Raffaele Sci. Inst., Milan, Italy;

⁸Univ. of BC, Vancouver, Canada; ⁹C&W Hosp., London, UK; ¹⁰OHSU, OR, US;

¹¹Albany Med. College, NY, US; ¹²CHU Gui de Chauliac, Montpellier, France;

¹³Clinique Medicale l'Actuel, Montreal, Canada; ¹⁴Univ. of Toronto, Toronto, Canada;

¹⁵Trimeris, NC, US; ¹⁶Roche, NJ, US

TORO 1 (US, Canada, Mexico, Brazil) & TORO 2 (Europe, Australia)

- **Population**

- Prior experience to ≥ 1 NRTI, ≥ 1 NNRTI, and ≥ 2 PI (≥ 1 PI for TORO 2)
- ≥ 6 months experience on each class for TORO 1 (≥ 3 months for TORO 2) or documented viral resistance or class intolerance
- HIV-1 RNA ≥ 5000 copies/mL

- **Design**

- Open label, randomized multi-center, international


- **Treatments (randomized 2:1)**

- Enfuvirtide (ENF): (90 mg sc bid) + OB
- Optimized Background (OB): 3–5 ARVs based on history, viral GT/PT

- **Efficacy analyses ENF+OB vs. OB**

TORO 1 & TORO 2: Protocol study design

Randomized 2:1, then
start ENF+OB or OB



*GT = Genotypic Testing; PT = Phenotypic Testing

**Criteria for virological failure based on 2 consecutive values:

1. $<0.5 \log_{10}$ decrease from baseline starting at week 6 and 8
2. $<1.0 \log_{10}$ decrease from baseline starting at week 14 and 16
3. $\geq 2 \log$ response and $>1 \log$ rebound at any time


Data following virological failure not included in primary efficacy analyses

TORO 1 & TORO 2: BL characteristics and prior ARV experience

	ENF+OB (N=661)	OB (N=334)
BL RNA (median, log ₁₀ copies/mL)	5.2	5.1
BL CD4+ cell count (median, cells/mm ³)	88	97
Number of prior ARVs (median)	12	12
Years since initiating ARVs (median)	7	7
Prior NRTI (median, years)	6.3	6.3
Prior NNRTI (median, years)	1.4	1.5
Prior PI (median, years)	3.8	4.0

The treatment benefit seen at week 24 is maintained at week 48:


Percent responders at week 24 and week 48 (ITT, DC+VF=F)



2 visits required to confirm viral load response


The treatment benefit seen at week 24 is maintained at week 48:

Percent responders at week 24 and week 48 (ITT, DC+VF=F)




2 visits required to confirm viral load response

CD4+ cell count adjusted means change from baseline – intent-to-treat population (LOCF) TORO 1 & TORO 2




The time to virological failure* was longer on ENF+OB compared to OB




* Protocol defined

Treatment benefit is seen across GSS subgroups for responders with HIV RNA <400 copies/mL, week 48 (ITT, DC+VF=Failure)




GSS	0	1	≥2
ENF+OB	112	194	344
OB	53	95	183

CD4+ cell count adjusted mean change from baseline, week 48 (ITT, LOCF) by BL GSS



GSS	0	1	≥2
ENF+OB	110	191	340
OB	52	93	180

Incidence of injection site reactions (ISRs)* by study week and by grade, 48 weeks



* based on pain or discomfort,
% of patients remaining on study

48 Week combined TORO 1 & TORO 2 exposure adjusted AEs (≥5 per 100 patient-years)

	ENF+OB N (Per 100 patient-years)	OB N (Per 100 patient-years)
Total exposure (patient-years)	557.04	162.13
diarrhoea	210 (37.7)	119 (73.4)
nausea	151 (27.1)	81 (50.0)
fatigue	134 (24.1)	61 (37.6)
headache	89 (16.0)	39 (24.1)
insomnia	88 (15.8)	32 (19.7)
peripheral neuropathy	86 (15.4)	22 (13.6)
vomiting	84 (15.1)	43 (26.5)
pyrexia	83 (14.9)	39 (24.1)
depression	80 (14.4)	27 (16.7)
upper respiratory tract infection	80 (14.4)	31 (19.1)
dermatitis	68 (12.2)	38 (23.4)
cough	64 (11.5)	23 (14.2)
weight decreased	62 (11.1)	17 (10.5)
nasopharyngitis	56 (10.1)	19 (11.7)
sinusitis	53 (9.5)	10 (6.2)
oral candidiasis	52 (9.3)	22 (13.6)
dizziness (excluding vertigo)	52 (9.3)	20 (12.3)
bronchitis	50 (9.0)	24 (14.8)

48 Week combined TORO 1 & TORO 2 exposure adjusted AEs (≥5 per 100 patient-years)

	ENF+OB N (Per 100 patient-years)	OB N (Per 100 patient-years)
Total exposure (patient-years)	557.04	162.13
diarrhoea	210 (37.7)	119 (73.4)
nausea	151 (27.1)	81 (50.0)
fatigue	134 (24.1)	61 (37.6)
headache	89 (16.0)	39 (24.1)
insomnia	88 (15.8)	32 (19.7)
peripheral neuropathy	86 (15.4)	22 (13.6)
vomiting	84 (15.1)	43 (26.5)
pyrexia	83 (14.9)	39 (24.1)
depression	80 (14.4)	27 (16.7)
upper respiratory tract infection	80 (14.4)	31 (19.1)
dermatitis	68 (12.2)	38 (23.4)
cough	64 (11.5)	23 (14.2)
weight decreased	62 (11.1)	17 (10.5)
nasopharyngitis	56 (10.1)	19 (11.7)
sinusitis	53 (9.5)	10 (6.2)
oral candidiasis	52 (9.3)	22 (13.6)
dizziness (excluding vertigo)	52 (9.3)	20 (12.3)
bronchitis	50 (9.0)	24 (14.8)

48 Week combined TORO 1 & TORO 2 exposure adjusted AEs (≥5 per 100 patient-years)

	ENF+OB N (Per 100 patient-years)	OB N (Per 100 patient-years)
Total exposure (patient-years)	557.04	162.13
diarrhoea	210 (37.7)	119 (73.4)
nausea	151 (27.1)	81 (50.0)
fatigue	134 (24.1)	61 (37.6)
headache	89 (16.0)	39 (24.1)
insomnia	88 (15.8)	32 (19.7)
peripheral neuropathy	86 (15.4)	22 (13.6)
vomiting	84 (15.1)	43 (26.5)
pyrexia	83 (14.9)	39 (24.1)
depression	80 (14.4)	27 (16.7)
upper respiratory tract infection	80 (14.4)	31 (19.1)
dermatitis	68 (12.2)	38 (23.4)
cough	64 (11.5)	23 (14.2)
weight decreased	62 (11.1)	17 (10.5)
nasopharyngitis	56 (10.1)	19 (11.7)
sinusitis	53 (9.5)	10 (6.2)
oral candidiasis	52 (9.3)	22 (13.6)
dizziness (excluding vertigo)	52 (9.3)	20 (12.3)
bronchitis	50 (9.0)	24 (14.8)

48 Week combined TORO 1 & TORO 2 exposure adjusted AEs (≥5 per 100 patient-years)

	ENF+OB N (Per 100 patient-years)	OB N (Per 100 patient-years)
Total exposure (patient-years)	557.04	162.13
bronchitis	50 (9.0)	24 (14.8)
appetite decreased	48 (8.6)	8 (4.9)
asthenia	43 (7.7)	14 (8.6)
anxiety	42 (7.5)	11 (6.8)
herpes simplex	41 (7.4)	15 (9.3)
abdominal pain	39 (7.0)	15 (9.3)
myalgia	39 (7.0)	9 (5.6)
pruritus	37 (6.6)	16 (9.9)
skin papilloma	37 (6.6)	5 (3.1)
*pneumonia	37 (6.6)	1 (0.6)
influenza	36 (6.5)	10 (6.2)
lymphadenopathy	33 (5.9)	2 (1.2)
folliculitis	32 (5.7)	13 (8.0)
pain in limb	32 (5.7)	13 (8.0)
dyspepsia	30 (5.4)	17 (10.5)
dry mouth	30 (5.4)	13 (8.0)
constipation	30 (5.4)	9 (5.6)
night sweats	28 (5.0)	12 (7.4)
dry skin	28 (5.0)	7 (4.3)


* Collapsed term including all pneumonias

48 Week combined TORO 1 & TORO 2 exposure adjusted AEs (≥5 per 100 patient-years)

	ENF+OB N (Per 100 patient-years)	OB N (Per 100 patient-years)
Total exposure (patient-years)	557.04	162.13
bronchitis	50 (9.0)	24 (14.8)
appetite decreased	48 (8.6)	8 (4.9)
asthenia	43 (7.7)	14 (8.6)
anxiety	42 (7.5)	11 (6.8)
herpes simplex	41 (7.4)	15 (9.3)
abdominal pain	39 (7.0)	15 (9.3)
myalgia	39 (7.0)	9 (5.6)
pruritus	37 (6.6)	16 (9.9)
skin papilloma	37 (6.6)	5 (3.1)
*pneumonia	37 (6.6)	1 (0.6)
influenza	36 (6.5)	10 (6.2)
lymphadenopathy	33 (5.9)	2 (1.2)
folliculitis	32 (5.7)	13 (8.0)
pain in limb	32 (5.7)	13 (8.0)
dyspepsia	30 (5.4)	17 (10.5)
dry mouth	30 (5.4)	13 (8.0)
constipation	30 (5.4)	9 (5.6)
night sweats	28 (5.0)	12 (7.4)
dry skin	28 (5.0)	7 (4.3)

* Collapsed term including all pneumonias

Incidence of bacterial pneumonia in TORO trials and historical controls



*Boschini *et al. Clin Inf Dis*, 1996; 23, 107
Hirschtick *et al. NEJM*, 1995; 333, 845
Polsky *et al. Ann Int Med*, 1986; 104, 38
Caiaffa *et al. Am J Resp Crit Care Med*, 1994; 150, 1493
Wallace *et al. Am Rev Resp Dis*, 1993; 148, 1523

Safety conclusions, 48 weeks

- **ENF added to a background regimen does not exacerbate most of the known toxicities associated with other ARVs**
- **The most common AE is ISRs, seen in almost all patients**
 - Generally mild to moderate
- **Increased rate of pneumonia observed in ENF+OB arm compared to control arm; drug relationship not established**
- **Hypersensitivity reactions have been attributed to ENF ($\leq 1\%$) and in some cases have recurred upon re-challenge**

Efficacy conclusions, 48 weeks

- **Percent responders (≥ 1 log drop from BL, < 400 or < 50 copies/mL) at week 48 were > 2 fold higher on ENF+OB compared to OB alone, all $P < 0.0001$**
- **Change from BL in CD4 count, as well as time to virological failure all significantly improved on ENF+OB compared to OB (all $P < 0.0001$)**
- **Treatment benefit was observed across all subgroups of GSS, including GSS=0**
- **Magnitude of benefit increases with more active ARVs in the OB regimen**
 - Subgroup analyses suggest that use of ENF with at least one active ARV in the OB regimen provides benefit similar or better than that provided with OB alone with ≥ 2 active ARVs

TORO 1: Acknowledgements

The Authors would like to express their gratitude to all of the patients that participated in the TORO 1 study as well as the numerous Roche and Trimeris study personnel who have worked closely with the following study investigators to bring the TORO 1 study to the 24 week primary analysis.

Dr P Alpert
Dr B Barnett
Dr N Basgoz
Dr G Beatty
Dr N Bellos
Dr T Campbell
Dr C Cohen
Dr A Collier
Dr E DeJesus
Dr J Dobkin
Dr J Eron
Dr C Farthing
Dr J Feinberg
Dr J Gallant
Dr M Goldman
Dr D Haas
Dr R Haubrich
Dr D Henry
Dr K Henry

Dr M Hirsch
Dr M Kilby
Dr O Klein
Dr D Kuritzkes
Dr J Lalezari
Dr H Lampiris
Dr M Lederman
Dr E Lefebvre
Dr O Leite
Dr J Montaner
Dr R Murphy
Dr R Myers
Dr L Nieto Cisneros
Dr M O'Hearn
Dr B Olmscheid
Dr P Piliero
Dr R Pollard
Dr S Rauf
Dr G Richmond

Dr S Riddler
Dr C Rivera-Vasquez
Dr D Rouleau
Dr K Sathasivam
Dr M Schechter
Dr J Sierra-Madero
Dr P Skolnik
Dr T Slom
Dr F Smaill
Dr C Steinhart
Dr M Thompson
Dr B Trottier
Dr S Walmsley
Dr J Wheat
Dr S Williams
Dr J Witek
Dr P Wolfe

TORO 2: Acknowledgements

The Authors would like to express their gratitude to all of the patients that participated in the TORO 2 study as well as the numerous Roche and Trimeris study personnel who have worked closely with the following study investigators to bring the TORO 2 study to the 24 week primary analysis.

Dr A Allworth
Dr J Anderson
Dr A Antinori
Dr K Aguirrebengoa
Dr K Arastéh
Dr M Battegay
Dr M Bloch
Dr N Bodsworth
Dr J Borleffs
Dr E Bouza
Dr G Carosi
Dr P Chavanet
Dr B Clotet
Dr N Clumeck
Dr R Colebunders
Dr D Cooper
Dr J-F Delfraissy
Dr P Dellamonica
Dr G Di Perri
Dr P Easterbrook
Dr M Fisher
Dr L Flamholc

Dr M Flepp
Dr H Gallais
Dr J-A Gastaut
Dr J Gatell Artigas
Dr P-M Girard
Dr J González García
Dr J González Lahoz
Dr K Gyllensten
Dr T Harrer
Dr B Hirschel
Dr J Hoy
Dr M Johnson
Dr C Katlama
Dr A Lafeuillade
Dr J Lange
Dr A Lazzarin
Dr C Leen
Dr F Mazzotta
Dr J-M Molina
Dr S Moreno
Dr M Nelson
Dr E Ortega

Dr J Pachon
Dr G Pastore
Dr F Pulido
Dr F Raffi
Dr D Rey
Dr J Reynes
Dr J Rockstroh
Dr N Roth
Dr W Rozenbaum
Dr R Rubio
Dr S Staszewski
Dr H-J Stellbrink
Dr A Stoehr
Dr F Suter
Dr A Telenti
Dr C Trépo
Dr M Van der Ende
Dr E Van Wijngaerden
Dr J-L Vilde
Dr D Vittecoq
Dr E Wilkins
Dr I Williams
Dr P Yeni